IP Library Granted Patent US 9,765,334
Granted Patent B2
US 9,765,334 · App. 12/994,411 · Granted Sep 19, 2017

Compositions and methods for prognosis of gastric cancer

Inventors: Moshe Hoshen (Jerusalem, IL); Raruch Brenner (Hod Hashron, IL)
Assignees: Rosetta Genomics, Ltd.; Mor Research Applications
C12N15/1135C12N15/111C12Q1/6886C12N2310/141C12N2320/12C12Q2600/112C12Q2600/118C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,334
App. No.
12/994,411
Granted
Sep 19, 2017
Kind
B2
Abstract

Described herein are compositions and methods for survival prediction in gastric cancer patients after surgical operation. The compositions are microRNA molecules associated with the prognosis of gastric cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.

Claims (10)

1. A method for determining a prognosis of gastric cancer in a human subject with gastric cancer, comprising:

(a) obtaining a biological sample from the subject;

(b) determining the expression level of SEQ ID NO: 1 in said sample by a nucleic acid hybridization method comprising contacting said sample with a probe, wherein the sequence of the probe consists of the complement of SEQ ID NO: 1, optionally attached to a linker sequence of 10-60 nucleotides, wherein the probe is attached to a solid substrate;

(c) comparing said expression level to a reference threshold expression level; and

(d) determining the prognosis of the gastric cancer based on the altered expression of SEQ ID NO: 1 in the sample relative to the reference threshold value, wherein increased expression of SEQ ID NO: 1 relative to the reference threshold is indicative of poor prognosis of gastric cancer in the subject.

2. The method of claim 1 , wherein said biological sample is selected from the group consisting of bodily fluid, a cell line and a tissue sample.

3. The method of claim 2 , wherein said tissue is a fresh, frozen, fixed, wax-embedded or formalin fixed paraffin-embedded (FFPE) tissue.

4. The method of claim 3 , wherein said tissue is a gastric tissue.

5. The method of claim 4 , wherein said gastric tissue is a tumor tissue at a specific stage.

6. The method of claim 1 , wherein the sequence of the probe consists of the complement of SEQ ID NO: 1 attached to a linker sequence of 10-60 nucleotides.

Assignments (2)
SECURITY INTEREST Recorded Dec 15, 2017
From: ROSETTA GENOMICS INC.; ROSETTA GENOMICS LTD; MINUET DIAGNOSTICS, INC.; CYNOGEN INC.
To: GENOPTIX, INC.
Reel/Frame 044899/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2010
From: HOSHEN, MOSHE; BRENNER, BARUCH
To: ROSETTA GENOMICS LTD.; MOR RESEARCH APPLICATIONS
Reel/Frame 025415/0836 →
Continuity (2)
Provisional Application 61057850 · Jun 1, 2008
Related Publication 20110177965A1 · Jul 21, 2011